Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 2 Rectal Obstruction, CTCAE"
Page 1
A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients.
Petersen SE, Thorsen LB, Hansen S, Petersen PM, Lindberg H, Moe M, Petersen JB, Muren LP, Høyer M, Bentzen L. Petersen SE, et al. Acta Oncol. 2022 Feb;61(2):179-184. doi: 10.1080/0284186X.2021.1979246. Epub 2021 Sep 20. Acta Oncol. 2022. PMID: 34543143 Clinical Trial.
RESULTS: Median follow-up (FU) time was 4.6 years. No persistent late CTCAE grade 3+ morbidity was observed. Prevalence of CTCAE grade 2+ GI morbidities varied from 0 to 6% at baseline throughout FU time, except for diarrhea, which was re …
RESULTS: Median follow-up (FU) time was 4.6 years. No persistent late CTCAE grade 3+ morbidity was observed. Prevalence …
Timing of High-Dose-Rate Brachytherapy With External Beam Radiation Therapy in Patients With Intermediate- and High-Risk Localized Prostate Cancer and Its Effects on Toxicity and Quality of Life: A Randomized Controlled Trial (THEPCA).
Choudhury M, Thomas SS, Cain A, Palvai S, Nageshwaran S, Zhang J, Hayden K, Cain A, Hoskin P, Ahmed I. Choudhury M, et al. Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):90-99. doi: 10.1016/j.ijrobp.2023.11.011. Epub 2023 Dec 30. Int J Radiat Oncol Biol Phys. 2024. PMID: 38163520 Clinical Trial.
METHODS AND MATERIALS: This was a single-center randomized trial in patients with intermediate- and high-risk localized prostate cancer who received HDR-BT before (Arm A) or after (Arm B) EBRT. Toxicities were graded using Common Terminology Criteria for Adverse Events ( …
METHODS AND MATERIALS: This was a single-center randomized trial in patients with intermediate- and high-risk localized prostate cancer who …